Global Liquid Biopsy Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2027

The Liquid Biopsy Market Report offers in-depth insights, revenue details, and other vital information regarding the target market, and the various trends, drivers, restraints, opportunities, and threats till 2027.

The Liquid Biopsy Market Report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint.

The global liquid biopsy market report has been segmented on the basis of application, type, biomarker, technology, and region.

This report is based on the synthesis, analysis, and interpretation of information gathered regarding the target market from various sources.

Liquid Biopsy Market Overview:

The Liquid Biopsy Market was valued at $2.4 billion in 2021 & is projected to reach $9.7 billion by 2027. It is expected to grow at an 28.9% CAGR between 2021 and 2027.

Our analysts have analyzed the information and data and gained insights using a mix of primary and secondary research efforts with the primary objective to provide a holistic view of the market.

In addition, an in-house study has been made of the global economic conditions and other economic indicators and factors to assess their respective impact on the market historically, as well as the current impact in order to make informed forecasts about the scenarios in the future.

Liquid biopsy is a simple and non-invasive cancer diagnostic method alternative to surgical biopsies, which is carried out by using biofluids such as blood, urine, plasma, and cerebral spinal fluid (CSF) samples that helps healthcare professionals for detecting cancer and tumor in early stage.

A blood sample is majorly used for the analysis of various cancers such as lung cancer, breast cancer, and leukemia. Urine and CSF samples are used for prostate cancer and brain cancer diagnosis.

Increasing incidence of cancer, rising preference for non-invasive procedures, and increasing government initiatives for liquid biopsy research and development activities are major factors expected to drive the growth of the global market over the forecast period.

In addition, technological advancements such as electric field-induced release and measurement (EFIRM) - Liquid Biopsy (eLB), which can assist in clinical treatment decisions are other factors expected to further fuel the growth of this market.

Furthermore, increasing global awareness regarding the advantages of multiple gene analysis is another factor expected to support the growth of the target market in the near future.

However, unclear regulatory scenarios and reimbursement policies are the major factors expected to restrain the growth of the global market over the forecast period.

An ongoing trend observed in the target market is increasing investment and support of various organizations such as the American Society of Clinical Oncology (ASCO) for the implementation of liquid biopsy.

Increasing competition among biotech companies and rising government investment in the healthcare industry for developing advanced and sophisticated methods of liquid biopsy is expected to create lucrative opportunities for players operating in the target market in the near future.

The market in North America dominates the target market in terms of revenue over the forecast period, owing to the increasing adoption of advanced diagnostic technologies (such as PCR and NGS), rising prevalence of cancer, and innovation in liquid biopsy products especially, in the US and Canada.

The market in the Asia Pacific is expected to register significant growth in terms of revenue over the forecast period, owing to improving healthcare infrastructure, rising awareness regarding cancer among individuals, and government policies in developing countries such as India, China, and Japan in the region.

Global liquid biopsy market segmentation:

Segmentation by type:

• Blood Sample-based
• Urine Sample-based
• Other Bio Fluids (Tissue fluids and Saliva) based

Segmentation by biomarker:

• Circulating Tumor Cells (CTC)
• Circulating Tumor DNA (ctDNA)
• Exosomes

Segmentation by technology:

• Multi-gene-parallel Analysis (NGS)
• Single Gene Analysis (PCR Microarrays)

Segmentation by application:

• Therapy Selection for Metastatic Breast Cancer (MBS)
• Therapy Selection for Other Metastatic Cancer
• Molecular Health Monitoring

Segmentation by region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa